Partnership Targets Cell Therapy Automation

The collaboration will see CTMC integrating specific ScaleReady technologies, including the Fresenius Kabi Lovo for large-volume cell processing and the Cue system for automated small-volume fill and finish. This directly targets the historically manual, open, and variable final steps of cell therapy production, aiming to enhance repeatability and reduce contamination risks. ScaleReady itself is a joint venture of Bio-Techne, Fresenius Kabi, and Wilson Wolf, created to combine their respective tools for cell culture, gene editing, and processing into a single, integrated platform. This move addresses the critical industry shift from highly manual, labor-intensive processes to industrialized and scalable manufacturing. Autologous therapies, which are patient-specific, have traditionally faced significant scaling challenges and high costs due to their "one batch, one patient" nature. By adopting closed, automated systems, CDMOs like CTMC can reduce process variability, lower the risk of human error, and begin to build more cost-effective production models required for broader patient access. The integration of such automated hardware is a foundational step for implementing advanced digital infrastructure like Laboratory Information Management Systems (LIMS) and Electronic Batch Records (EBRs). Automating data capture from processing systems into an EBR ensures data integrity, facilitates GMP compliance with regulations like 21 CFR Part 11, and eliminates the errors and delays associated with manual transcription. This creates a robust, end-to-end digital thread for each manufacturing batch. Data streams from these integrated systems are the essential fuel for developing digital twins of the bioprocess. By creating a virtual replica of the manufacturing workflow, teams can run in-silico simulations to optimize process parameters, predict the impact of raw material variability, and de-risk scale-up before consuming expensive materials and physical resources. This aligns with the push toward Industry 4.0 principles to make CGT manufacturing more predictive and efficient. CTMC itself is a strategic joint venture between National Resilience Inc. and the MD Anderson Cancer Center, designed to accelerate the development and manufacturing of cell therapies for cancer. This partnership model, combining industrial expertise with a leading academic cancer center, aims to shorten the path from discovery to IND and commercial readiness. This collaboration occurs as the cell and gene therapy CDMO market is projected to grow significantly, with some forecasts predicting it will exceed $74 billion by 2034. Despite a recent risk-averse funding environment that has led to underutilization of some CDMO capacity, the demand for specialized